(Q33232427)

24 July 2017

1 reference

title

Systematic review of systemic therapy for advanced or recurrent endometrial cancer (English)

1 reference

recurrent endometrial cancer

24 July 2017

1 reference

1 reference

1 reference

Mark S Carey

1

1 reference

24 July 2017

Christine Gawlik

2

1 reference

24 July 2017

Michael Fung-Kee-Fung

3

1 reference

24 July 2017

Alexandra Chambers

4

1 reference

24 July 2017

Tom Oliver

5

1 reference

24 July 2017

Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group

6

1 reference

24 July 2017

language of work or name

English

0 references

publication date

24 January 2006

1 reference

24 July 2017

1 reference

24 July 2017

101

1 reference

24 July 2017

1

1 reference

24 July 2017

158-167

1 reference

Stage I endometrial adenocarcinoma: treatment results in 835 patients.

24 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Novel strategies for systemic treatment of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Current treatment options for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.019

10.1016/J.YGYNO.2005.11.019

7 January 2021

Identifiers

DOI

1 reference

24 July 2017

1 reference